Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Oct 31, 2007

165_ip_2007-10-31_e3b1af03-6572-4ae6-b526-2011268ad524.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Third Quarter / Nine Months 2007 Results

Analyst Meeting, October 31, 2007

Safe Harbor Statement

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with the Securities and Exchange Commission and the German Exchange Commission "Deutsche Börse".

1. Business Update

2. Financials and Outlook

3. Q&A Session

Business Update

* including clinics where FME has an interest of at least 10%

Q3 2007 – Continued Strong Momentum

(
lu
d
ing
im
i
in
)
-t
te
2
0
0
6
ex
c
o
ne
e
ms
R
e
v
e
n
u
e		 \$
2
4
2
6
m
,		 9
%
+
N
i
t
e
n
c
o
m
e		 \$
1
8
1
m		 2
7
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
6
1		 2
8
%
+
  • X Continued strong performance across all segments and regions again in Q3
  • X Continued high earnings momentum in Q3

Clearly on Track to Achieve the Upper End of Guidance

Q3 2007 – Strong Revenue Growth

Total Revenue Increased 9% to \$ 2,426 m *

Dialysis Services - Global

Strong Overall Revenue Growth

\$
i
i
l
l
i
n
m
o
n
s		 Q
3
2
0
0
6		 Q
3
2
0
0
7		 G
h
t
r
o
w		 c
c
1)
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
4
5
,		 1
4
9
4
,		 3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 2
3
2		 3
0
7		 3
2
%		 2
3
%
1)
T
l
t
o
a		 1
6
7
7
,		 1
8
0
1
,		 %
7		 %
6

X Continued strong growth in Europe of 10%cc (9% organic) and Asia-Pacific of 151%cc (19% organic), y-o-y

1) Q3 2006 revenue adjusted for sale of perfusion business in the amount of US\$ 27 m cc = constant currency

Dialysis Services - Global

Organic Revenue Growth of 5%

Q
3
2
0
0
7		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
h
t
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 %
5
+
c
c		 3
%
+		 1
2
%
+
c
c
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 3
6
%
+		 3
0
%
+		 4
9
%
+
R
t
t
t
e
e
n
e
p
e
r
r
e
a
m
e
n
v
u		 1)
\$
3
2
3		 \$
1
5
3
G
h
t
r
o
w		 1
%
+		 7
%
+
c
c
T
(
i
i
l
l
i
)
t
t
r
e
a
m
e
n
s
n
m
o
n		 6
6		 4
6		 2
0
G
h
t
r
o
w		 6
%
+		 3
%
+		 1
4
%
+

1) including Mexico

cc = constant currency

1)

Dialysis Services - United States

Revenue per Treatment up 5% excluding EPO

Quality Outcomes - Global

Anemia Outcomes improving in Europe

N
t
h
o
r		 A
i
m
e
r
c
a		 E M
E
A
f
F
M
E
i
%
t
t
o
p
a
e
n
s		 Q
3
2
0
0
6		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 Q
3
2
0
0
7
/
≥
1
2
K
t
V		 9
%
5		 9
%
5		 9
3
%		 9
4
%
H
l
b
i
≥
1
1
/
d
l
e
m
o
g
o
n
g		 8
1
%		 %
8
0		 6
8
%		 %
7
3
A
l
b
i
≥
3
/
d
l
5
u
m
n
g		 8
0
%		 8
0
%		 8
7
%		 8
%
5
H
i
t
l
i
t
i
d
o
s
p
a
a
o
n
a
s
z
y		 1
1
5		 1
1
1		 7
5		 7
6

X North America: 2 days reduction in hospitalization since 2004

Quality Outcomes - United States

Anemia Management

Focuses on quality outcomes for patients in line with K/DOQI guidelines

Data Source: Clinical Performance Management (CPM) Data / Legacy FME U.S. clinics

Dialysis Products - Global

Continued Excellent Growth

\$
i
i
l
l
i
n
m
o
n
s		 Q
3
2
0
0
6		 Q
3
2
0
0
7		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
i
l.
I
l
R
)
t
n
c
n
e
r
n
a
e
e
n
e
v
u		 0
7
7		 8
2
1		 1
6
%		 1
1
%
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 5
3
0		 6
2
5		 1
8
%		 1
2
%
N
h
A
i
t
o
r
m
e
r
c
a		 1
4
1		 1
6
7		 1
8
%		 1
8
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 3
8
9		 4
5
9		 1
8
%		 9
%

cc = constant currency

Highlights - Global

* Excluding one-time items. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Highlights – Global: Dialysis Products

  • X Strong growth in products well above market of 18% X PhosLo sales fully in line with expectations

  • being up +79%, y-o-y

  • X Strong growth in products above market at 17%, y-o-y (8%cc)

  • X 5008 HD machine unit sales up 135%, y-o-y

  • X Strong product sales growth of 14%cc

  • X Organic revenue growth in China Q3 of 46%cc and Nine Months of 31%cc, y-o-y

Highlights – Global: Dialysis Services

  • X FDA Advisory Panel's decision supports Anemia Management Practices
  • X Active dialogue with U.S. legislators on medically appropriate care for ESRD patients

  • X Strong Revenue/treatment despite EPO discussion

  • X Service Growth in Eastern Europe of 18%cc, ytd

  • X Increase in revenue per treatment of 4%
  • X Online HDF reimbursement recognized in Spain

X Strong treatment growth in Q3 of 119% (14% excl. Jiate Excelsior)

Q
l
i
t
a
u
y		 X
D
i
i
i
l
i
i
d
d
i
t
t
r
n
g
s
p
e
r
o
r
q
a
n
p
r
o
c
s
a
n
s
e
r
c
e
s
v
u
u
y
u
v
G
h
t
r
o
w		 X
A
l
d
d
l
t
t
c
c
e
e
r
a
e
e
n
o
v
o
e
v
e
o
p
m
e
n
s
X
F
i
d
h
t
t
t
t
o
c
s
o
n
o
r
g
a
n
c
r
e
e
n
e
a
n
p
e
r
r
e
a
m
e
n
g
r
o
u
v
u
w
G
h
t
r
o
w
D
i
r
e
r
s
v		 X
S
I
d
P
d
M
k
h
t
t
n
c
r
e
a
s
e
r
o
c
a
r
e
a
r
e
u
X
Q
R
i
b
B
d
l
i
t
t
e
m
u
r
s
e
m
e
n
a
s
e
o
n
u
a
y
X
C
E
i
f
l
i
i
N
k
t
p
a
n
s
o
n
o
n
c
e
o
r
x
w
X
R
l
P
h
e
n
a
a
r
m
a

Financials Q3 and Outlook

1) Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 Q
3
2
0
0
6		 Q
3
2
0
0
7		 G
h
t
r
o
w
*
N
t
e
r
e
e
n
e
v
u		 2
2
3
4
,		 2
4
2
6
,		 9
%
2)
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 3
5
5		 3
9
7		 1
2
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
9		 1
6.
4
2)
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 1
0
0		 9
5
2)
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 2
5
5		 3
0
2		 1
8
%
2)
I
T
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
0
8		 1
1
5
T
t
a
x
r
a
e		 4
2
%		 %
3
8
M
i
i
i
t
t
t
n
o
r
n
e
r
e
s
y		 4 6
2)
N
i
t
e
n
c
o
m
e		 1
4
3		 1
8
1		 2
7
%

* 6% growth at constant currency, 6% organic growth

1) Excluding one-time items in 2006

2) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

1) Profit & Loss

\$
i
i
l
l
i
n
m
o
n
s		 M
9
2
0
0
6		 9
M
2
0
0
7		 G
h
t
r
o
w
*
N
t
e
r
e
v
e
n
u
e		 6
1
4
7
,		 7
1
5
1
,		 1
6
%
2)
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 9
3
6		 1
1
5
2
,		 2
3
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
2
5		 1
6.
1
2)
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 2
4
1		 2
8
1
2)
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 6
9
5		 8
7
1		 2
%
5
2)
I
T
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 2
8
0		 3
3
1
T
t
a
r
a
e
x		 4
0
%		 3
8
%
M
i
i
i
t
t
t
n
o
r
y
n
e
r
e
s		 1
0		 2
0
2)
N
i
t
e
n
c
o
m
e		 4
0
5		 5
2
0		 2
8
%

* 14% growth at constant currency, 7% organic growth

1) Excluding one-time items in 2006

2) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

EBIT margin

Overall Solid Improvement

North America

International

in %

* Excluding one-time items

Days Sales Outstanding (DSO)

Best in Industry

\$
i
i
l
l
i
n
m
o
n
s		 Q
3
2
0
0
6		 Q
3
2
0
0
7		 G
h
t
r
o
w
)
1
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
e
o
p
e
r
a
n
g
a
c
e
s
v
y
v		 2
6
1		 3
8
2
f r
1
5.
8
%
o
ev
en
ue		 4
7
%
1)
C
i
l
d
i
t
t
(
)
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e		 (
)
1
1
3		 (
)
1
2
3
F
C
h
F
l
r
e
e
a
s
o
w		 1
4
8		 2
9
5		 7
4
%
1)
A
i
i
i
f
d
i
i
t
t
t
t
c
q
s
o
n
s
n
e
o
e
s
r
e
s
u
v
u
,		 (
)
1
0		 (
2
4
)
C
F
h
F
l
f
i
i
i
t
t
r
e
e
a
s
o
w
a
e
r
a
c
q
u
s
o
n
s		 1
3
8		 2
3
5

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

\$
i
i
l
l
i
n
m
o
n
s		 M
9
2
0
0
6		 9
M
2
0
0
7		 G
h
t
r
o
w
1)
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
v
e
y
o
p
e
r
a
n
g
a
c
v
e
s		 6
6
3		 8
9
0
f r
1
2.
4
%
o
ev
en
ue		 3
4
%
1)
C
i
l
d
i
t
t
(
)
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e		 (
)
2
3
7		 (
)
3
6
4
C
F
h
F
l
r
e
e
a
s
o
w		 3
9
0		 2
6
5		 3
5
%
1)
f
A
i
i
i
d
i
i
t
t
t
t
c
q
s
o
n
s
n
e
o
e
s
r
e
s
u
v
u
,		 (
)
4
4		 (
1
1
0
)
C
f
F
h
F
l
i
i
i
t
t
r
e
e
a
s
o
w
a
e
r
a
c
q
u
s
o
n
s		 3
4
6		 4
1
6

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

De-leveraging ahead of schedule

* including non-cash charges and excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Continued Strong Growth in Earnings per Share

Earnings per Share

CAGR =16%

\$
i
i
l
l
i
n
m
o
n
s		 G
i
d
a
n
c
e
u
N
R
t
e
e
v
e
n
u
e
s		 \$
9
5
0
0
>
,
N
I
t
e
n
c
o
m
e		 \$
6
8
0
5
7
5
-
L
i
t
e
e
r
a
g
e
r
a
o
v
(
/
)
D
b
E
B
I
T
D
A
t
e		 3
0
<
C
E
d
i
i
i
t
a
p
a
n
a
c
q
s
o
n
s
x
u		 \$
6
0
5
~

X Clearly on Track for the Upper End of Net Income Guidance

X Leverage Ratio Target already Achieved after Nine Months

Thank You for your interest in Fresenius Medical Care !

Fresenius Medical Care

The World's Leading Renal Therapy Company

Third Quarter / Nine Months 2007 Results

Analyst Meeting, October 31, 2007

D
b
t
e		 Q
3
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
1)
S
ho
t
te
bo
ing
(
inc
l.
A
/
R
)
r
rm
rro
w
s
p
ro
g
ra
m		 7
6		 3
3
1		 1
5
1		 4
1
9		 9
0
S
ho
bo
ing
fro
la
d p
ies
t
te
te
t
+
r
rm
rro
w
s
m
re
ar		 4
6		 5 1
9		 6 3
0
Cu
ion
f
lon
de
b
d c
i
l
lea
b
l
ig
ion
t p
t
te
t a
ta
t
+
rre
n
or
o
g-
rm
n
ap
se
o
a
s		 4
6		 1
6
0		 1
2
6		 2
3
0		 9
0
Cu
f
fe
Se
t p
t
ion
Tr
t
Pr
d
i
t
ies
+
rre
n
or
o
us
e
rre
cu
r		 6
6
5
Lo
-te
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
les
t p
t
ion
+
ng
rm
n
ap
se
o
a
s,
s c
ur
re
n
or		 4,
0
3
2		 3,
8
2
9		 7
0
7		 5
4
5		 1,
1
1
2
Tr
Pr
fe
d
Se
i
ies
(
f c
ion
)
t
t
t o
t p
t
+
us
e
rre
cu
r
ne
ur
re
n
or		 6
4
8		 1,
2
4
5		 1,
1
8
8		 1,
2
9
7		 1,
2
4
2
Ac
iva
b
le
i
iza
ion
ts
t
t
+
co
un
rec
e
se
cu
r
p
ro
g
ra
m		 0 0 0 0 1
8
5
To
l
de
b
ta
t
=		 1
3
5,
5		 9
5,
5
7		 2,
1
9
1		 2,
4
9
7		 2,
2
2
7

All numbers are in \$ millions

E
B
I
T
D
A		 2)
Q
3
2
0
0
7		 2)
F
Y
2
0
0
6
(pr
o f
)
orm
a		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
La
t
tw
lve
t
hs
t
ing
inc
(
E
B
I
T
)
s
e
m
on
o
p
er
a
om
e		 1,
5
3
3		 1,
3
6
7		 9
3
9		 8
5
2		 7
5
7
La
t
tw
lve
t
hs
de
ia
t
ion
d a
t
iza
t
ion
+
s
e
m
on
p
rec
an
mo
r		 3
4
7		 3
2
6		 2
1
5		 2
3
3		 2
1
6
No
h c
ha
+
n-c
as
rg
es		 3
7		 3
5		 1
4		 1
3		 1
3
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 1,
9
1
7		 1,
7
2
8		 1,
2
0
4		 1,
0
9
8		 9
8
6

1) A/R securitization program off-balance sheet in 2003 and included in short term borrowings from 2004 onwards 2) Excluding restructuring costs and in-process R&D

All numbers are in \$ millions

E
l
R
t
e
r
n
a
e
e
n
e
x
v
u		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 t
h
g
row		 cc
In
te
t
io
l
du
t r
rn
a
na
p
ro
c
ev
en
ue		 2
4
5		 4
3
9		 1
9
%
+		 1
1
%
+
In
l re
te
rna
ve
nu
e
-		 (
)
6
5		 (
)
5
0
Ex
l r
te
rn
a
ev
en
ue
=		 4
9
5		 3
8
9		 1
8
%
+		 9
%
+
No
h
Am
ica
du
t
t r
r
er
p
ro
c
ev
en
ue		 2
9
7		 2
6
8		 1
1
%
+
In
l re
te
rna
ve
nu
e
-		 (
)
1
3
0		 (
)
1
2
7
Ex
te
l r
rn
a
ev
en
ue
=		 1
6
7		 1
4
1		 1
8
%
+
T
O
T
A
L
du
t r
p
ro
c
ev
en
ue		 8
2
1		 7
0
5		 1
6
%
+		 1
1
%
+
In
l re
te
rna
ve
nu
e
-		 (
)
1
9
6		 (
)
1
7
5
Ex
l r
te
=
rn
a
ev
en
ue		 6
2
5		 5
3
0		 1
8
%
+		 1
2
%
+
C
i
l
d
i
(
)
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 9
2
0
0
M
7		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 9
M
2
0
0
6
Pu
ha
f p
ty
lan
t a
d
ip
t
rc
se
o
ro
p
er
p
n
eq
u
m
en
,		 3
8
6		 1
3
4		 1
1
5		 2
8
8
fro
f p
Pr
ds
le
ty
lan
t a
d
ip
t
oc
ee
m
sa
o
ro
p
er
p
n
eq
u
m
en
-
,		 (
)
2
2		 (
)
1
1		 (
)
2		 (
)
1
5
Ca
i
l e
d
i
(
)
ta
tu
t
p
xp
en
re
ne
=		 3
6
4		 1
2
3		 1
1
3		 2
7
3

cc = constant currency

O
f
f
t
i
b
t
i
i
t
p
e
r
a
n
g
p
e
r
o
r
m
a
n
c
e
e
o
r
e
o
n
e-
m
e
e
m
s		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 h
t
g
row
Op
ing
inc
(
E
B
I
T
)
t
er
a
om
e		 3
9
7		 3
4
9		 1
4
%
Ga
in
fro
d
ive
t
i
tu
tru
tu
in
+
m
s
re
re
s
c
r
g		 0 6
Op
ing
inc
(
E
B
I
T
)
be
fo
im
i
t
t
te
er
a
om
e
re
on
e-
e-
ms		 3
9
7		 3
5
5		 1
2
%
Ne
in
t
co
m
e		 1
8
1		 1
3
9		 3
0
%
Lo
fro
d
ive
i
in
t
tu
tru
tu
ss
m
s
re
re
s
c
r
g
,		 0 4
Ne
inc
be
fo
im
i
t
t
te
om
e
re
on
e-
e-
ms		 1
8
1		 1
4
3		 2
7
%

All numbers are in \$ millions

f
&
P
i
t
L
A
t
r
o
o
s
s
c
c
o
u
n		 Q
3
2
0
0
6		 On
im
i
t
tem
e-
e
s		 Q
3
2
0
0
6
lu
d
ing
im
i
t
tem
ex
c
on
e-
e
s
Ne
t r
ev
en
ue		 2,
2
3
4		 2,
2
3
4
Op
t
in
in
(
E
B
I
T
)
er
a
g
co
m
e		 3
4
9		 *
6		 3
5
5
E
B
I
T-
in
(
%
)
m
ar
g		 1
6
5.		 1
9
5.
In
te
t e
t
res
xp
en
se
ne
,		 (
)
1
0
0		 (
)
1
0
0
In
be
fo
in
ta
co
m
e
re
co
m
e
xe
s		 2
4
9		 6 2
5
5
Inc
Ta
om
e
x e
xp
en
se		 (
1
0
6
)		 (
2
)		 (
1
0
8
)
Ta
(
)
te
%
x r
a		 4
2		 4
2
M
ino
i
in
ty
te
t
r
re
s		 (
)
4		 (
)
4
Ne
t
in
co
m
e		 1
3
9		 4 1
4
3

* Restructuring costs of US\$ 7 m, less gain from divestiture of US\$ 1 m

All numbers are in \$ millions

P
f
i
&
L
A
t
t
r
o
o
s
s
c
c
o
u
n		 M
9
2
0
0
6		 On
im
i
t
tem
e-
e
s		 M
9
2
0
0
6
lu
d
ing
im
i
t
tem
ex
c
on
e-
e
s
Ne
t r
ev
en
ue		 6,
1
4
7		 6,
1
4
7
Op
(
)
t
in
in
E
B
I
T
er
a
g
co
m
e		 9
6
4		 *
(
)
2
8		 9
3
6
E
B
I
T-
in
(
)
%
m
ar
g		 1
5.
7		 1
5.
2
In
te
t e
t
res
xp
en
se
ne
,		 (
2
)
5
5		 **
1
4		 (
2
4
1
)
fo
In
be
in
ta
co
m
e
re
co
m
e
xe
s		 7
0
9		 (
)
1
4		 6
9
5
Inc
Ta
om
e
x e
xp
en
se		 (
)
3
1
4		 3
4		 (
)
2
8
0
Ta
(
%
)
te
x r
a		 4
4
%		 4
0
M
ino
i
in
ty
te
t
r
re
s		 (
1
0
)		 (
1
0
)
Ne
t
in
co
m
e		 3
8
5		 2
0		 4
0
5
O
i
i
N
h
A
i
t
t
p
e
r
a
n
g
n
c
o
m
e
o
r
m
e
r
c
a		 Q
3
2
0
0
6		 9
M
2
0
0
6
Re
ve
nu
e		 1,
6
1
3		 4,
3
6
7
Op
ing
inc
(
E
B
I
T
)
t
er
a
om
e		 2
5
7		 0
4
7
(
%
f r
)
E
b
i
t m
in
in
ar
g
o
ev
en
ue		 %
1
5.
9		 %
1
6.
1
On
im
i
t
te
e-
e-
m
s		 6 (
3
0
)
E
b
i
t m
in
(
in
%
f r
)
be
fo
-t
im
i
te
ar
g
o
ev
en
ue
re
o
ne
e
m
s		 1
6.
3
%		 1
4
%
5.

* US\$ 40 m gain from divestiture, less US\$ 10 m restructuring costs and US\$ 2 m costs for transformation of the legal form of the Company

** Write-off of deferred financing costs

Attachment V

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

C
h
F
l
a
s
o
w		 Q
3
2
0
0
7		 9
M
2
0
0
7
Ac
is
i
ion
t
q
s
u		 (
)
2
6		 (
)
1
4
0
Pr
ds
fro
d
ive
i
t
tu
oc
ee
m
s
res		 2 3
0
Ac
is
i
t
io
t o
f
d
ive
t
i
tu
q
u
ns
ne
s
re
s
,		 (
2
4
)		 (
1
1
0
)
C
h
F
l
a
s
o
w		 Q
3
2
0
0
6		 Ta
for
ts
x p
ay
me
n
ior
p
r
y
ea
rs		 C
G
R
is
i
ion
t
ac
q
u		 Q
3
2
0
0
6
Ne
t c
h
i
de
d
by
t
in
t
iv
i
t
ies
as
p
ro
v
o
p
er
a
g
ac		 1
5
3		 9
9		 9 2
6
1
Ca
i
l
Ex
d
i
(
)
ta
tu
t
p
p
en
res
ne		 (
1
1
3
)		 (
1
1
3
)
Fr
Ca
h
F
low
ee
s		 4
0		 9
9		 9 1
4
8
Ac
is
i
ion
d
d
ive
i
t
t
tu
q
s a
n
s
res
u		 (
)
8		 (
)
2		 (
)
1
0
Fr
Ca
h
F
low
f
is
i
io
d
d
ive
i
te
t
t
tu
ee
s
a
r a
cq
u
ns
a
n
s
re
s		 3
2		 9
9		 7 1
3
8
C
h
F
l
a
s
o
w		 9
M
2
0
0
6		 Ta
for
ts
x p
ay
me
n
ior
p
r
y
ea
rs		 R
C
G
is
i
ion
t
ac
q
u		 9
M
2
0
0
6
Ne
t c
h
i
de
d
by
t
in
t
iv
i
t
ies
as
p
ro
v
o
p
er
a
g
ac		 4
6
5		 9
9		 9
9		 6
6
3
Ca
(
)
i
l
Ex
d
i
ta
tu
t
p
p
en
res
ne		 (
)
2
7
3		 (
)
2
7
3
Fr
Ca
h
F
low
ee
s		 1
9
2		 9
9		 9
9		 3
9
0
Ac
is
i
ion
d
d
ive
i
t
t
tu
q
u
s a
n
s
res		 (
3,
6
8
2
)		 3,
6
3
8		 (
4
4
)
Ca
f
Fr
h
F
low
te
is
i
t
io
d
d
ive
t
i
tu
ee
s
a
r a
cq
u
ns
a
n
s
re
s		 (
)
3,
4
9
0		 9
9		 3,
7
3
7		 3
4
6

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Oliver Maier

Head of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Mob.: +49-(0)173-6522-712 Mail: [email protected]

North America:

Terry L. Proveaux Tel.: +1-800-948-2538Fax.: +1-615-345-5605Mob.: +1-615-618-2987 bbMail: [email protected]

Ordinary shares

WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Reminder …

For recent updates, please have a look at our webpage. Navigation around

www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our share

More from Fresenius Medical Care AG & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.